Aneurysm Biology, Screening, Surveillance, and Decision Frameworks

18.1Definition and presentation

An abdominal aortic aneurysm is an infrarenal aortic diameter of 3.0 cm or greater, measured consistently by ultrasound or cross-sectional imaging ACR 2023 · Chaikof 2002. The condition reflects a chronic degenerative process of the aortic wall, strongly influenced by age, smoking exposure, sex, family history, and systemic atherosclerosis.

Most small aneurysms are clinically silent and are detected incidentally or through population screening. The principal risk is rupture, which rises steeply with increasing diameter. Distal embolization from an aneurysm can also present with blue toes or acute limb ischemia. An embolic presentation attributable to the aneurysm requires urgent vascular assessment even below an elective diameter threshold. Clinical embolization changes management; a specific turbulence-driven mechanism is not established by this guideline ESVS 2024.

The following broad diameter bands reproduce historical estimates used in the 2003 guidance, not calibrated individual predictions for a contemporary surveillance population:

These larger-diameter ranges provide historical context, not exact current annual probabilities Brewster 2003. Ordinary asymptomatic degenerative AAA, infected aneurysm and saccular disease require distinct assessment. Inflammatory AAA is not automatically a higher-rupture-risk category, and “oval” is not a validated independent treatment threshold. Contemporary surveillance and repair decisions use symptoms, serial measurements, sex, anatomy and fitness alongside diameter ESVS 2024. The clinical implication of a given diameter is modified by several features:

• Growth rate
• Saccular morphology
• Presence of symptoms
• Patient size and sex
• Operative fitness

18.2Screening and population trials

Population screening targets groups with a high pre-test probability to detect clinically important aneurysms via one-time abdominal ultrasound. The strongest mortality benefit is observed in older men with a history of smoking.

In the MASS (2002) trial of community-dwelling men aged 65 to 74 years, an invitation for a one-time ultrasound screening demonstrated a 42% relative risk reduction in aneurysm-related mortality at four years, an effect that persisted at 10 and 13 years MASS 13-year (2012) · MASS 10-year (2009) · MASS (2002). Pooled evidence syntheses report long-term mortality odds ratios of 0.60 to 0.65 in screened older men USPSTF Evidence Synthesis 2019 · Cochrane 2007.

Contemporary Swedish follow-up adds information about subaneurysmal aortas rather than replacing the randomized screening trials. Among 1,020 men screened at age 65 with aortic diameter 25–29 mm, 940 had follow-up. All 41 who subsequently reached 55 mm had already reached 30 mm at the five-year examination. This supports reassessment of that specific screened male population; it does not justify five-year intervals for established larger AAA or for women AAA 2021.

18.3Diagnosis and surveillance

For appropriately selected patients with small asymptomatic AAA, immediate open repair has not shown a survival advantage over structured surveillance. The ADAM trial reported by Lederle and colleagues in 2002 is one of the randomized studies underlying this approach. Continue surveillance until symptoms, diameter, verified growth or another specific feature warrants repair assessment ESVS 2024 · ADAM 2002.

Surveillance intervals scale inversely with aneurysm diameter. Aneurysms are tracked using consistent ultrasound methodology, transitioning to computed tomography or magnetic resonance angiography when ultrasound windows are poor or anatomy mapping is required for repair planning ESVS 2024 · SVS 2018. Pooled aneurysm growth rates average 2.38 mm per year AAA Growth Rates 2024. Apparent rapid interval growth of >= 10 mm per year requires remeasurement with the same imaging modality to exclude measurement noise before advancing to repair.

These are ESVS sex-specific recommendations: IIa B for men and IIa C for women, with life expectancy, suitability for future repair and preferences considered. They are not identical to the older SVS subaneurysmal schedule. New attributable symptoms require assessment rather than waiting for the next scheduled scan ESVS 2024.

18.4Medical management

Medical therapy is directed at cardiovascular risk reduction rather than aneurysm-specific growth modification. Smoking cessation is the single most effective modifiable intervention and carries a strong SVS recommendation: continued smoking accelerates aneurysm expansion and raises rupture risk, so every current smoker with an AAA should be supported to quit SVS 2018. Statins are recommended for cardiovascular prevention and are associated with lower perioperative mortality during aneurysm repair. Observational data associate statin use with a mean growth-rate reduction of 0.82 mm per year, but heterogeneity limits their use as an aneurysm-specific indication Extended Screening 2020 · Statin Meta-analysis 2018.

Fluoroquinolone exposure is observationally associated with a higher short-term risk of aortic events (relative risk 9.13). Alternative antibiotics are utilized when feasible in patients with known aortic disease Fluoroquinolones Review 2026. Metformin demonstrates an inverse observational association with aneurysm presence and growth (approximately 0.8 mm per year lower), but no trial evidence supports initiating glucose-lowering therapy solely for aneurysm control Metformin Meta-analysis 2021 · Bell 2026.

18.5Treatment decisions and repair thresholds

Elective repair is indicated when the predicted rupture risk during continued observation exceeds the combined risk of intervention. Treatment choices follow an ordered pathway governed by absolute diameter, anatomy, and procedural fitness.

The management logic proceeds stepwise:

1. Decide surveillance versus repair. For asymptomatic fusiform AAA, combine sex-specific diameter guidance with operative risk, life expectancy and preferences. Saccular anatomy prompts separate assessment, including exclusion of infection; it does not automatically override every dimensional consideration ESVS 2024.
2. Optimize medical management. Cardiovascular risk is modified for all patients, integrating statins and avoiding fluoroquinolones where feasible.
3. Select endovascular versus open repair. Anatomic suitability for EVAR is necessary but not sufficient to make it universally preferable. Compare perioperative risk, expected longevity, durability, need for later reintervention, ability to complete surveillance and patient preference. A patient unsuitable for standard EVAR may need open repair or assessment for a complex endovascular solution rather than implantation outside standard device requirements ESVS 2024.
4. Address urgent modifiers. New pain or tenderness attributable to the aneurysm, distal embolization or suspected rupture requires prompt vascular assessment, even below an elective diameter threshold. A stable symptomatic nonruptured AAA may undergo brief rapid assessment and optimization before urgent repair; do not require severe pain. Apparent rapid growth needs measurement confirmation and is not, by itself, proof of rupture ESVS 2024.
5. Confirm no-intervention candidacy. Patients who are entirely unfit for the physiologic stress of intervention are assigned to watchful waiting, independent of aneurysm size.

18.6Special populations and post-repair surveillance

Patient sex, family history, and regional prevalence influence baseline risk and pathway management. Women generally present with lower overall prevalence but display worse short-term outcomes following endovascular repair, including elevated odds of 30-day and in-hospital mortality in pooled analyses Sex Differences EVAR 2026. Repair thresholds are correspondingly downshifted for women.

First-degree family history alters pre-test probability and selectively prompts screening evaluation. Asian populations demonstrate an overall aneurysm prevalence of 1.30%, escalating to 2.56% in subsets with high cardiovascular risk. This regional variation informs specific regional frameworks, such as the KVSS threshold band of 50 to 55 mm for elective repair in men KVSS 2026 · Asian Prevalence 2021.

Endovascular repair commits the patient to lifelong surveillance to assess seal zones, sac geometry, and complications such as endoleak or device migration. Computed tomography angiography remains the foundational modality because it comprehensively maps branch vessels and device position. Contrast-enhanced colour duplex ultrasound offers high diagnostic accuracy (pooled sensitivity 0.94, specificity 0.95 for endoleak) and is used to reduce cumulative radiation and contrast exposure in stable patients CEUS Endoleak 2017. Changes in sac volume identify expansion missed by maximum diameter alone AAA Volume 2023. Although late rupture after endovascular repair is uncommon (cumulative incidence 0.9%, mean time to event 37 months), it carries high perioperative mortality (32%) and reinforces the necessity of structured surveillance for any patient fit for rescue reintervention ESVS 2024 · SVS 2018 · Late Rupture 2015. SVS recommends a baseline contrast-enhanced CT angiogram within 30 days of EVAR; if there is no endoleak and no sac enlargement at one month, imaging repeats at 12 months and then converts to colour duplex ultrasound annually, reserving CT angiography for a new endoleak or sac growth. ESVS 2024 instead specifies early CTA within 30 days and subsequent risk stratification. Selected low-risk standard EVAR patients may undergo less frequent imaging during the first five years, whereas higher-risk findings require closer follow-up; all remain in a long-term surveillance plan. This must not be described as the same universal annual-duplex schedule.

18.7Areas of controversy

Screening indications for women remain unsettled. Due to an imprecise trial base and lower population prevalence, recommendations diverge across organizations, precluding a single standardized approach USPSTF 2019 · Cochrane 2007.

Open versus endovascular repair involves a different trade-off from the decision whether repair is needed. EVAR generally reduces early operative burden but commits the patient to device surveillance and possible reintervention; open repair carries greater initial physiologic burden but may offer a durability advantage in a suitable patient. Anatomy, life expectancy, operative fitness and informed preference determine the balance, not a universal endovascular-first rule. Chapters 20 and 21 cover open aneurysm repair and EVAR respectively; Chapter 16, “Device evaluation and reporting frameworks” and “Clinical integration and surveillance strategy”, develops the device-durability and follow-up implications ESVS 2024.

Morphologic repair triggers also lack strict numeric boundaries. While saccular morphology commands earlier intervention, guidelines have not established a universal dimensional offset to define early repair precisely ESVS 2024 · SVS 2018. Similarly, the use of pharmacotherapy, including statins and metformin, for aneurysm growth modification relies solely on observational signals, as no randomized trials have confirmed an aneurysm-specific mechanism or benefit Statin Meta-analysis 2018 · Bell 2026.

Further reading

• Editor's Choice - Systematic Review and Meta-Analysis of Contemporary Abdominal Aortic Aneurysm Growth Rates. (2024). Contemporary AAA growth synthesis. AAA Growth Rates 2024
• Primary Care Screening for Abdominal Aortic Aneurysm: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. (2019). AAA screening evidence review, distinct from the USPSTF recommendation statement. USPSTF Evidence Synthesis 2019